Suture Ease — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Suture Ease is a commercial-stage medical device company specializing in laparoscopic surgical closure systems. Its core technology, the CrossBow Fascial Closure System, addresses a critical need for reliable and reproducible closure of trocar sites, with over 150,000 clinical cases reported globally. The company also markets the Securus System as a cost-effective, high-quality replacement for Carter-Thomason style closure devices. Led by an experienced management team with deep medical device and surgical expertise, Suture Ease is positioned in the growing minimally invasive surgery market.

Surgical

Technology Platform

Proprietary mechanical systems for laparoscopic fascial closure, centered on a unique 'snare guide' and suture passer technology designed for reproducible trocar site suturing.

Opportunities

The global expansion of minimally invasive surgery creates a large, recurring need for reliable port closure devices.

Significant cost pressure on hospitals presents a major opportunity for the Securus System as a high-quality, lower-cost alternative to established products.

Successful commercialization of the next-generation LongBow device could further expand the company's market reach and technological leadership.

Risk Factors

Facing competition from entrenched players in the laparoscopic closure market.

Revenue is heavily reliant on one flagship product family (CrossBow) and one replacement line (Securus).

As a small, private company, it faces execution risks in scaling sales and marketing against larger competitors.

Competitive Landscape

Suture Ease competes in the laparoscopic closure device market against established medical device companies offering mechanical closure systems, such as those originally based on the Carter-Thomason design. Its strategy is to differentiate through its unique CrossBow technology for improved reproducibility and through cost competition with its Securus System. It must displace surgeon familiarity with existing tools and navigate hospital procurement processes.

More companies in Drug Delivery & Formulation →More companies in United States →